InfoNet Logo  

New Mexico AIDS InfoNet Fact Sheet Number 444

NELFINAVIR

(VIRACEPT)


Eslabón a la Versión Español

 PrinterPrint

this Fact Sheet on a single page using:

 Microsoft Word

Adobe Acrobat

 More information on Downloading

& Printing Fact Sheets


WHAT IS NELFINAVIR?

Nelfinavir, also called Viracept®, is a drug used for antiviral therapy. It is

manufactured by Agouron Pharmaceuticals. Nelfinavir is a protease

inhibitor. These drugs prevent the protease enzyme from working.

HIV protease acts like a chemical scissors. It cuts the raw material

for HIV into specific pieces needed to build a new virus. Protease

inhibitors “gum up” these scissors.


WHO SHOULD TAKE

NELFINAVIR?

Nelfinavir was approved as an antiviral drug for people with

HIV infection. There are no absolute rules about when to start

antiviral drugs. You and your doctor should consider your T-cell count, your viral

load, any symptoms you are having, and your attitude about

taking HIV medications. Fact Sheet

411 has more information about guidelines

for the use of antiviral medications.

If you take nelfinavir with other antiviral drugs, you can

reduce your viral load to extremely low levels, and increase your

T-cell counts. This should mean staying healthier longer.


WHAT ABOUT DRUG

RESISTANCE?

Many new copies of HIV are mutations. They are slightly different

from the original virus. Some mutations can keep multiplying even

when you are taking an antiviral drug. When this happens, the

drug will stop working. This is called “developing resistance”

to the drug. See Fact Sheet 414

for more information on resistance.

Sometimes, if your virus develops resistance to one drug, it

will also have resistance to other antiviral drugs. This is called

“cross-resistance”.

Resistance can develop quickly. It is very important to

take antiviral medications according to instructions, on schedule,

and not to skip or reduce doses.


HOW

IS NELFINAVIR TAKEN?

Nelfinavir is taken by mouth as a capsule. The normal dose

is 750 milligrams (mg) three times a day. The capsules are 250mg,

so you will take 3 capsules at a time.

Late in 1999, the FDA approved twice-daily dosing of nelfinavir

at 1250 mg per dose. This means taking 5 capsules at a time. If

you want to change how often you take nelfinavir, talk to your

doctor. Different doses are used in some combinations. Be

sure you know how much nelfinavir your doctor has prescribed for

you, and when and how to take each dose.

The former capsules dissolved quickly and were difficult to

swallow. A film-coated tablet was approved in March 2000 and replaced

the old capsules.

Nelfinavir should be taken with meals. It should be stored

at room temperature and protected from moisture, freezing, or

excessive heat.


WHAT

ARE THE SIDE EFFECTS?

The most common side effects of nelfinavir are diarrhea, weakness,

headache, nausea, and abdominal pain. None of these side effects

seem to be very serious. The diarrhea in most cases can be controlled

with over-the-counter medications.


HOW DOES NELFINAVIR REACT WITH OTHER DRUGS?

Nelfinavir is broken down by the liver and can interact with

other drugs that also use the liver. Combining these drugs

can change the amount of each drug in your bloodstream and cause

an under- or overdose. Drugs to watch out for include Viagra,

several antihistamines, sedatives, drugs to lower cholesterol

and anti-fungal drugs. Make sure that your doctor knows about

ALL drugs you are taking.

If you are taking nelfinavir and ddI,

you should take ddI one hour before or two hours after nelfinavir.

Some birth control pills may not work if you are taking nelfinavir.

Talk to your doctor about how to prevent an unwanted pregnancy.

The herb St. John’s Wort (See

Fact Sheet 729) lowers the blood levels of some protease inhibitors.

Tell your doctor about any herbs or other supplements that you

use.


 Revised August 16, 2002

HomeGo

to InfoNet Main Page

Card FileGo to

Index of Fact Sheets

Question markClick

here if you have questions

The New Mexico AIDS InfoNet is a project of the

New Mexico AIDS Education and Training Center

Partially funded by the National Library of Medicine

and the New Mexico Department of Health